Sign In
Last checked at 
21 May 2026 14:50
21 May 2026
Cambridge Cognition Holdings plc
("Cambridge Cognition" or the "Company")
Result of AGM
Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, held its Annual General Meeting ("AGM") earlier today at the registered office of the Company; Tunbridge Court, Tunbridge Lane, Bottisham, Cambridge, CB25 9TU and announces that all resolutions put forward were duly passed.
Proxy votes were received in respect of 59.3% of the Company's issued share capital. The votes cast were as follows:
| Resolution | Votes For | Percent of votes cast For | Votes Against | Percent of votes cast Against | Votes Withheld |
1 | To approve the 2025 Report and Accounts | 27,607,286 | 100% | - | - | 22,265 |
2 | To approve the 2025 Directors' Remuneration Report1 | 27,576,829 | 99.83% | 47,714 | 0.17% | 5,008 |
3 | To appoint the auditors | 27,595,679 | 99.92% | 22,660 | 0.08% | 11,212 |
4 | To authorise the Directors to set the auditors' remuneration | 27,602,281 | 99.99% | 2 | 0.01% | 27,268 |
5 | To re-elect Stuart Gall as a Director | 27,602,093 | 99.92% | 22,440 | 0.08% | 5,018 |
6 | To re-elect Jon Kempster as a Director | 27,601,693 | 99.92% | 22,840 | 0.08% | 5,018 |
7 | To re-elect Nick Rodgers as a Director | 27,601,693 | 99.92% | 22,840 | 0.08% | 5,018 |
8 | To elect Rob Baker as a Director | 27,602,273 | 99.92% | 22,260 | 0.08% | 5,018 |
9 | To elect Ronald Openshaw as a Director | 27,602,273 | 99.92% | 22,260 | 0.08% | 5,018 |
10 | Authority to allot shares | 27,572,233 | 99.79% | 57,313 | 0.21% | 5 |
11 | Authority to disapply pre-emption rights2 | 27,569,635 | 99.80% | 54,898 | 0.20% | 5,018 |
12 | Authority to purchase own shares on the market2 | 24,196,722 | 99.90% | 25,412 | 0.10% | 3,407,417 |
Notes
1. Indicates an advisory vote.
2. Indicates a Special Resolution requiring 75% of votes cast to be carried.
Enquiries:
Cambridge Cognition Holdings plc Rob Baker, Chief Executive Officer Ronald Openshaw, Chief Financial Officer
| Tel: 01223 810700 press@camcog.com
|
Cavendish Capital Markets Limited (NOMAD and Joint Broker) Geoff Nash / Elysia Bough / Joe Smith Harriet Ward Nigel Birks
| Tel: 020 7220 0500 Corporate Finance Corporate Broking LS Specialist Sales
|
Singer Capital Markets Limited (Joint Broker) Amber Higgs / James Serjeant / Daniel Ingram
| Tel: 020 7496 3000 |
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care.
Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts. The Company has identified four market sectors:
· Clinical Studies for new pharmaceuticals;
· Academic Research for scientists to understand CNS disorders;
· Healthcare to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and,
· Consumer Health & Wellness to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health.
For further information, visit: www.cambridgecognition.com.
Follow the stocks
